Join us for this webinar to have the answers to these questions.
It will be an online presentation and Q&A given by Grace Fu Palma, CEO of ChinaMed Device.
In Spring 2018, China’s State Council unveiled a plan to reshuffle government ministries. Along with the reshuffling plan, the China Food and Drug Administration (CFDA) has now changed its name to the National Medical Product Administration (NMPA). The name change is just the tip of iceberg. The NMPA (CFDA) changes will offer both opportunities and challenges to many foreign companies targeting the Chinese market. ChinaMed is offering the online webinar to update you in the following areas:
Also, email us at info@ChinaMedDevice.com to receive our 2018 NMPA (CFDA) Almanac (soon to be published in January). It is a publication of the complete major 2018 NMPA (CFDA) listing of regulation, guidelines, technical standards, adverse events, etc.
ChinaMed Device, LLC (www.ChinaMedDevice.com), a Boston headquartered company, provides regulatory and commercialization turnkey solutions for western medical device, IVD, CDx and combination products to enter China. Our NMPA (CFDA) regulatory services include: RA, regulatory strategy, regulatory submissions, clinical evaluation reports (CER), clinical trials, QA, GMP and post-market compliance. Our commercialization services include: market assessment research, reimbursement, partnership strategies, and distribution qualification. We are a NMPA (CFDA) certified legal agent with offices in Boston and Beijing enabling us to service our clients 24/7.